PRDX5 and cancer: The effects of thioredoxin reductase inhibition by auranofin, the primary mode of action in both anti-rheumatoid arthritis and anti-cancer roles [45-48], can be significantly augmented by combination with disulfiram [35], another CUSP9* drug.